Objective To assess the pharmacodynamic activity and safety of rising single and multiple
doses of intravenous quinaprilat compared with placebo in patients with New York Heart …

The hemodynamic and neurohumoral effects of single and multiple doses of intravenous
quinaprilat were assessed and compared with placebo in a double-blind design. The study …

Angiotensin converting enzyme inhibitors are now firmly established in the treatment of
patients with chronic heart failure (CHF). Their beneficial acute and chronic hemodynamic …

1. Twenty‐four elderly patients with stable, chronic congestive heart failure, NYHA II‐IV,
requiring addition of an ACE inhibitor to their existing therapy were randomised to receive …

A two-part hemodynamic trial of the efficacy and safety of quinapril hydrochloride was
conducted in 26 patients with congestive heart failure (NYHA Class III or IV) who had not …

To determine the safety and efficacy of single oral doses of quinapril in the treatment of
congestive heart failure (CHF), an open-label, hemodynamic trial was conducted in 11 …

Quinapril is converted to quina prilat, a long-acting angiotensin con verting enzyme (ACE)
inhibitor, and is currently being studied for the treatment of hypertension and con gestive …

The pharmacokinetics of quinapril and its active metabolite quinaprilat were studied in 12
patients with congestive heart failure (CHF) after multiple oral doses of 10 mg quinapril twice …

Objective: To compare the efficacy and safety of captopril twice a day with quinapril once a
day for the treatment of mild to moderate congestive heart failure in a multicentre, double …

Angiotensin converting enzyme (ACE) inhibitors are of proven value in patients with severe
chronic heart failure (CHF). Studies of the effects of ACE inhibitors on exercise capacity and …